Conversion Labs, Inc. (CVLB) is a public company listed on NASDAQ. There were no new wire items for CVLB in the last 30 days. The most recent was published Mar 19, 2021.
Latest news
25 items- 13D/GSEC Form SC 13D filed by Conversion Labs, Inc.SC 13D - LifeMD, Inc. (0000948320) (Subject)
- SECSEC Form 8-K filed8-K - LifeMD, Inc. (0000948320) (Filer)
- INSIDERSEC Form 4: David Happy Walters was granted 1,200,000 units of Common Stock, increasing ownership by 149% to 1,336,300 units4 - LifeMD, Inc. (0000948320) (Issuer)
- INSIDERSEC Form 4: Harold Eric Yecies bought $100,400 worth of Common Stock (5,000 units at $20.08)4 - LifeMD, Inc. (0000948320) (Issuer)
- INSIDERSEC Form 4: Michael Brad Roberts bought $102,500 worth of Common Stock (5,000 units at $20.50)4 - LifeMD, Inc. (0000948320) (Issuer)
- SECSEC Form 8-K filed8-K - CONVERSION LABS, INC. (0000948320) (Filer)
- PRConversion Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol, LFMDNEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the market today under its new name, LifeMD, Inc., and Nasdaq ticker symbol, LFMD. The stock’s new CUSIP number will be 53216B 104. “Our new name reflects our evolution from a healthcare-focused performance marketing business into a leading provider of personalized, direct to patient telehealth services,” stated Justin Schreiber, LifeMD’s co-founder and CEO. “Our vision is to radically change healthcare by making access to the best physicians and prescription medications easily accessible, convenient, and aff
- ANALYSTBTIG Research reiterated coverage on Conversion Labs with a new price targetBTIG Research reiterated coverage of Conversion Labs with a rating of Buy and set a new price target of $40.00 from $15.00 previously
- PRConversion Labs to Become Life MD™ with Launch of New Concierge Telehealth ServicesNEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, will change its name to Life MD™ on February 22, followed by the official launch of its subscription-based primary care and concierge services offering designed to positively transform all aspects of a patient’s healthcare. “We see our new name reflecting our evolution and expansion from a branded telemedicine products company into a leading provider of end-to-end concierge telehealth services,” stated company co-founder and CEO, Justin Schreiber. “Life MD expresses our desire to have a deeper connection to the daily lives of our patients who desire more conven
- SECSEC Form 8-K filed8-K - CONVERSION LABS, INC. (0000948320) (Filer)
- SECSEC Form 8-K filed8-K - CONVERSION LABS, INC. (0000948320) (Filer)
- INSIDERSEC Form 3: David Marc Benathen claimed ownership of 15,000 units of Restricted Stock Units3 - CONVERSION LABS, INC. (0000948320) (Issuer)
- INSIDERSEC Form 3 filed by Corey Deutsch3 - CONVERSION LABS, INC. (0000948320) (Issuer)
- PRConversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial OfficerNEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of
- ANALYSTB. Riley FBR initiated coverage on Conversion Labs with a new price targetB. Riley FBR initiated coverage of Conversion Labs with a rating of Buy and set a new price target of $35.00
- SECSEC Form 8-K filed8-K - CONVERSION LABS, INC. (0000948320) (Filer)
- INSIDERSEC Form 3: Michael Brad Roberts claimed ownership of 10,000 units of Restricted Stock Units3 - CONVERSION LABS, INC. (0000948320) (Issuer)
- INSIDERSEC Form 4: Justin Schreiber gifted 20,000 units of Common Stock4 - CONVERSION LABS, INC. (0000948320) (Issuer)
- SECSEC Form 8-K filed8-K - CONVERSION LABS, INC. (0000948320) (Filer)
- SECSEC Form 8-K/A filed8-K/A - CONVERSION LABS, INC. (0000948320) (Filer)
- PRConversion Labs Increases Stake in Fast-Growing SaaS SubsidiaryNEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has increased its stake in its legacy LegalSimpli Software subsidiary from 51% to 82.6%, largely from the conversion of long-term debt held by Conversion Labs into equity. LegalSimpli operates PDFSimpli.com, an online software-as-a-service (SaaS) that allows users to easily create, edit, convert, sign and share PDF documents. The subsidiary is currently operating at an annualized run-rate revenue of more than $18 million. “Since we first invested in LegalSimpli in 2018, its growth has been explosive, driven by its exceptionally talented management team and
- SECSEC Form 8-K filed8-K - CONVERSION LABS, INC. (0000948320) (Filer)
- SECSEC Form 8-K filed8-K - CONVERSION LABS, INC. (0000948320) (Filer)
- PRConversion Labs Expects 2020 Revenue up 205% to Record $38.0 Million, Subscription ARR up 525% to $26.0 MillionNEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, reported preliminary unaudited results for its fourth quarter and full year ended December 31, 2020. Revenue for the fourth quarter is expected to total $13.6 million, up 265% from $3.7 million in the fourth quarter of 2019. Revenue for the full year is expected to total $38.0 million, up 205% from $12.5 million in 2019. “Our strong performance in 2020 demonstrated our ability to provide accessible healthcare to an increasing number of patients across the country,” stated Conversion Labs CEO, Justin Schreiber. “We ended the year exceptionally strong, with D
- SECSEC Form 3 filed by Ii David Anthony Puopolo3 - CONVERSION LABS, INC. (0000948320) (Issuer)
CVLB FAQ
6 questionsWhat is the latest news on CVLB?
Quantisnow has not tracked any new filings, ratings or press releases for CVLB in the last 30 days. The most recent wire item was published on March 19, 2021.Where does CVLB stock trade?
Conversion Labs, Inc. (CVLB) is listed on NASDAQ.What sector and industry is CVLB in?
Conversion Labs, Inc. operates in the n/a sector.When did Conversion Labs, Inc. go public?
Conversion Labs, Inc. (CVLB) completed its IPO in n/a.What companies are similar to CVLB?
Notable peers in the same industry include HCXY (Hercules Capital, Inc.), ACCP (Accelerated Pharma, Inc.), ACLL (ACell, Inc.), DWEQ (AdvisorShares Dorsey Wright Alpha Equal Weight ETF), DWAW (AdvisorShares Dorsey Wright FSM All Cap World ETF). Compare CVLB side-by-side with any of them on Quantisnow.How can I track CVLB on Quantisnow?
Quantisnow aggregates Conversion Labs, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CVLB to receive live email and push alerts on every new disclosure.